Objective: To examine the association between angiotensin-converting enzyme (ACE) inhibitor use and clinical outcome after primary vascular reconstruction in a population-based follow-up study. Methods: All Danish patients undergoing primary vascular surgical reconstruction between 1996 and 2007 were included. For each ACE user up to 5 nonuser was identified using propensity score matching followed by Cox regression. All drugs were included as time-dependent variables. Results: Totally 17 495 matched patients with a median follow-up period of 582 days were included. All-cause mortality was 20.4% for ACE users and 24.9% for nonusers (adjusted hazard ratio [adj HR] 0.88, 95% confidence interval [CI] 0.81-0.96). The cumulative risk of myocardial infarction was 6.2% for ACE users and 4.7% for nonusers (adj HR 1.20, 95%CI 1.03-1.39). Cumulative risk of new vascular surgery was 24.0% for ACE users and 23.1% for nonusers (adj HR 1.21, 95% CI 1.13-1.30). No differences were seen concerning stroke and major amputation. Conclusion: The ACE use was associated with lower all-cause mortality but also an increased long-term risk of recurrent vascular reconstruction.
WeltenGMSchoutenOHoeksSE. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol. 2008;51(16):1588–1596.
2.
NorgrenLHiattWRDormandyJANehlerMRHarrisKAFowkesFG. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–S67.
3.
HirschATHaskalZJHertzerNR. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113(11):e463–e654.
4.
De BackerGAmbrosioniEBorch-JohnsenK. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force Of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Arch Mal Coeur Vaiss. 2004;97(10):1019–1030.
5.
SchroederTVEbskovLBEgebladMUnderekstremitetsiskæmi, forebyggelse og behandling, vol. 2. Den Danske almindelige lægeforening, 2005. Ref. type: Raport.
6.
RadackKDeckC.Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med. 1991;151(9):1769–1776.
7.
YusufSSleightPPogueJBoschJDaviesRDagenaisG.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145–153.
8.
OstergrenJSleightPDagenaisG. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25(1):17–24.
9.
HirschATDuprezD. The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease. Vasc Med. 2003;8(4):273–278.
10.
CoppolaGRomanoGCorradoEGrisantiRMNovoS. Peripheral artery disease: potential role of ACE-inhibitor therapy. Vasc Health Risk Manag. 2008;4(6):1179–1187.
11.
AhimastosAALawlerAReidCMBlomberyPAKingwellBA. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med. 2006;144(9):660–664.
12.
RobertsDHTsaoYLingeKMcLoughlinGABreckenridgeA. Double-blind comparison of captopril with nifedipine in hypertension complicated by intermittent claudication. Angiology. 1992;43(9):748–756.
13.
SonechaTNNicolaidesANKyprianouP. The effect of enalapril on leg muscle blood flow in patients with claudication. Int Angiol. 1990;9(1):22–24.
14.
StaessenJAWangJGThijsL. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358(9290):1305–1315.
15.
PedersenCBGotzscheHMollerJOMortensenPB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. 2006;53(4):441–449.
16.
LaustsenJJensenLPHansenAK. Accuracy of clinical data in a population based vascular registry. Eur J Vasc Endovasc Surg. 2004;27(2):216–219.
17.
AndersenTFMadsenMJorgensenJMellemkjoerLOlsenJH.The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3):263–268.
18.
CharlsonMEPompeiPAlesKLMacKenzieCR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
19.
DeyoRACherkinDCCiolMA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.
20.
RubinDB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 pt 2):757–763.
21.
RubinDB. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med. 2007;26(1):20–36.
22.
AustinPC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424.
23.
AustinPC. Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J Thorac Cardiovasc Surg. 2007;134(5):1128–1135.
24.
FeringaHHvan WaningVHBaxJJ. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol. 2006;47(6):1182–1187.
25.
KennonSBarakatKHitmanGA. Angiotensin-converting enzyme inhibition is associated with reduced troponin release in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2001;38(3):724–728.
26.
ShariffNDunbarCMatsumuraME. Relation of pre-event use of inhibitors of the renin-angiotensin system with myocardial infarct size in patients presenting with a first ST-segment elevation myocardial infarction. Am J Cardiol. 2010;106(5):646–649.
27.
FeringaHHvan WaningVHBaxJJ. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol. 2006;47(6):1182–1187.
28.
De BuyzereMLClementDL. Management of hypertension in peripheral arterial disease. Prog Cardiovasc Dis. 2008;50(4):238–263.
29.
MehlerPSCollJREstacioREslerASchrierRWHiattWR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation. 2003;107(5):753–756.
30.
MurabitoJMEvansJCNietoKLarsonMGLevyDWilsonPW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J. 2002;143(6):961–965.
31.
LaneDALipGY.Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev. 2009;(4):CD003075.
32.
ManciniGBHenryGCMacayaC. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 1996;94(3):258–265.
33.
AhimastosAADartAMLawlerABlomberyPAKingwellBA. Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients. J Hypertens. 2008;26(5):1037–1042.
34.
ThygesenSKChristiansenCFChristensenSLashTLSorensenHT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83.
